Verition Fund Management
MCRB icon

Verition Fund Management’s Seres Therapeutics MCRB Stock Holding History

Verition Fund Management’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-15,709
Closed -$227K – 3398
2024
Q2 		$227K Buy
+15,709
New +$262K ﹤0.01% 2513
2023
Q4 		– Sell
-3,105
Closed -$148K – 2548
2023
Q3 		$148K Buy
+3,105
New +$237K ﹤0.01% 2054

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Verition Fund Management's MCRB Position: Q3 2024 in Review

Verition Fund Management sold out of Seres Therapeutics (MCRB) in Q3 2024, closing a stake of 15,709 shares — an estimated $227K sold.

Verition Fund Management first reported a position in MCRB in Q3 2023 and held it in 2 quarters. The position peaked at $227K in Q2 2024. 77 funds tracked by Wall St. Rank hold MCRB as of Q3 2024.

  • Verition Fund Management reported no remaining Seres Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Verition Fund Management sold 15,709 Seres Therapeutics shares in Q3 2024, an estimated $227K.
  • Verition Fund Management first reported a position in Seres Therapeutics in Q3 2023 and held it in 2 quarters.
  • Verition Fund Management's Seres Therapeutics position peaked at $227K in Q2 2024.
  • 77 funds tracked by Wall St. Rank held Seres Therapeutics as of Q3 2024.

Based on Verition Fund Management's 13F filing for Q3 2024, filed 14 Nov 2024.